金石亚药(300434) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥232,007,882.58, representing an increase of 18.13% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 reached ¥24,808,867.41, a significant increase of 264.15% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥22,051,954.33, up 281.74% from the previous year[4] - The company's basic earnings per share for Q3 2022 was ¥0.06, reflecting a 200.00% increase compared to the same period last year[4] - Total operating revenue for the period was CNY 711,438,394.76, a decrease of 2.4% from CNY 731,928,047.69 in the previous period[15] - Net profit attributable to shareholders of the parent company increased to CNY 107,008,293.50, up 32.1% from CNY 80,944,550.26[16] - Basic and diluted earnings per share rose to CNY 0.27, compared to CNY 0.20 in the previous period[16] - The company reported a total profit of CNY 128,909,102.88, up from CNY 99,405,024.07 in the previous period[16] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,668,779,411.06, a decrease of 3.59% from the end of the previous year[4] - The company's total assets as of September 30, 2022, amount to ¥2,668,779,411.06, a decrease from ¥2,768,127,717.25 at the beginning of the year[13] - Current assets decreased from ¥946,786,046.66 to ¥879,865,267.01, reflecting a decline of approximately 7.1%[12] - Total liabilities decreased from ¥606,118,784.35 to ¥474,631,727.43, a reduction of about 21.7%[13] - The total equity attributable to shareholders of the parent company was CNY 2,162,465,481.65, an increase from CNY 2,083,751,254.61[14] Cash Flow - Operating cash flow for the year-to-date period was ¥122,361,316.43, an increase of 16.64% compared to the previous year[7] - Net cash flow from operating activities was CNY 122,361,316.43, an increase of 16.6% from CNY 104,906,427.50[17] - The cash inflow from operating activities totaled CNY 721,000,195.17, compared to CNY 788,888,511.99 in the previous period[17] - The net cash flow from financing activities was -61,863,857.48 CNY, indicating a significant outflow compared to the previous period[18] - The total cash and cash equivalents at the end of the period amounted to 258,146,823.18 CNY, an increase from the beginning balance of 234,721,831.30 CNY[18] - The net increase in cash and cash equivalents for the quarter was 23,424,991.88 CNY, contrasting with a significant decrease of -168,833,764.73 CNY in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,486[9] - The largest shareholder, Gao Yaping, holds 25.11% of shares, totaling 100,878,929 shares[9] - The company has a total of 69,822,051 shares under lock-up agreements, primarily due to management restrictions[11] Investment and Expenses - The company reported a significant increase in asset disposal income of ¥17,741,675.29, compared to a loss of ¥1,296.13 in the same period last year[7] - The company’s investment activities generated a net cash flow of -¥38,948,649.08, a decrease of 82.88% compared to the previous year[7] - Research and development expenses increased to CNY 30,020,328.40, up 8.9% from CNY 27,762,817.13[15] Audit and Compliance - The company did not undergo an audit for the third quarter report[19]